Lexibook Linguistic Electronic System SA (ALLEX)
Euronext Paris · France · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 8.000 |
|---|---|
| 52-week range | 4.500 – 8.500 |
| Return, 1 month / 3 months | −4.5% / −1.7% |
| Return, 1 year / 3 years | +36.1% / +270.4% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 42 |
| Volatility (1 year) | 52.3% |
| Worst drawdown (1 year) | -32.3% |
| Average daily value traded | 0.00M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Lexibook Linguistic Electronic System is a French company that makes electronic products for children and language learners. Its range covers electronic dictionaries and translators, educational laptops and tablets, and electronic toys and games sold under the Lexibook brand. Customers are mainly families, schools and retailers, and the products are marketed in France and other European countries. The company is based in France and develops its goods around language learning, study aids and child-friendly electronics.
On this site Lexibook Linguistic Electronic System SA appears as a stock on the Euronext Paris (France), code ALLEX, with prices in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Lexibook Linguistic Electronic System SA (ALLEX) trades on the Euronext Paris in France. It last closed at EUR 8.000 on 22 October 2026.
Its price-based Market X-Ray is 66 out of 100 (a fair price profile), ranking 151 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 36.1% and over the last three months it fell 1.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 93 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 16.6% | ||
| From 52-week high | -5.7% | ||
| Momentum | 84 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | -1.7% | ||
| 6-month return | 43.4% | ||
| 12-month return, skipping the last month | 42.5% | ||
| Stability (higher is calmer) | 45 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 52.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -32.3% | ||
| Liquidity | 26 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M EUR | ||
| Zero-volume days | 6.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −4.1% |
|---|---|
| 1 month | −4.5% |
| 3 months | −1.7% |
| 6 months | +43.4% |
| 1 year | +36.1% |
| 3 years | +270.4% |
| 5 years | +116.2% |
Signals
| 50-day / 200-day average | 8.142 / 6.863 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.154 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.